These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23748853)

  • 1. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
    Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
    Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
    Stückrath I; Rack B; Janni W; Jäger B; Pantel K; Schwarzenbach H
    Oncotarget; 2015 May; 6(15):13387-401. PubMed ID: 26033453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
    Eichelser C; Stückrath I; Müller V; Milde-Langosch K; Wikman H; Pantel K; Schwarzenbach H
    Oncotarget; 2014 Oct; 5(20):9650-63. PubMed ID: 25333260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
    Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
    Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
    Zeng Z; Chen X; Zhu D; Luo Z; Yang M
    Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
    Niedźwiecki S; Piekarski J; Szymańska B; Pawłowska Z; Jeziorski A
    Ginekol Pol; 2018; 89(8):415-420. PubMed ID: 30215459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
    Anfossi S; Giordano A; Gao H; Cohen EN; Tin S; Wu Q; Garza RJ; Debeb BG; Alvarez RH; Valero V; Hortobagyi GN; Calin GA; Ueno NT; Woodward WA; Reuben JM
    PLoS One; 2014; 9(1):e83113. PubMed ID: 24416156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.
    Asaga S; Kuo C; Nguyen T; Terpenning M; Giuliano AE; Hoon DS
    Clin Chem; 2011 Jan; 57(1):84-91. PubMed ID: 21036945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers.
    García-Magallanes N; Beltran-Ontiveros SA; Leal-León EA; Luque-Ortega F; Romero-Quintana JG; Osuna-Ramirez I; Barbosa-Jasso M; Arámbula-Meraz E
    J Cancer Res Ther; 2020; 16(6):1223-1228. PubMed ID: 33342777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
    Li J; Song ZJ; Wang YY; Yin Y; Liu Y; Nan X
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-34a modulates ErbB2 in breast cancer.
    Wang Y; Zhang X; Chao Z; Kung HF; Lin MC; Dress A; Wardle F; Jiang BH; Lai L
    Cell Biol Int; 2017 Jan; 41(1):93-101. PubMed ID: 27813227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
    Yang L; Feng Y; Qi P; Xu S; Zhou Y
    J Biol Regul Homeost Agents; 2016; 30(4):1041-1045. PubMed ID: 28078851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic factors associated with de novo metastatic breast cancer.
    Shen T; Siegal GP; Wei S
    Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.
    Schwarzenbach H; Milde-Langosch K; Steinbach B; Müller V; Pantel K
    Breast Cancer Res Treat; 2012 Aug; 134(3):933-41. PubMed ID: 22350790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
    Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
    Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.
    Chen W; Cai F; Zhang B; Barekati Z; Zhong XY
    Tumour Biol; 2013 Feb; 34(1):455-62. PubMed ID: 23238818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.